Bellicum Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Bellicum Pharmaceuticals non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Charles Grass	Principal Accounting Officer	2.8yrs	Nessun dato	Nessun dato
Joseph Senesac	Senior Vice President of Technical Operations & Quality	2.1yrs	Nessun dato	Nessun dato
Alan Smith	Chief Scientific Officer	3.7yrs	US$791.68k	Nessun dato

2.8yrs

Durata media

63yo

Età media

Gestione esperta: Il team dirigenziale di BPXA è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Stephen Davis	Independent Director	8.6yrs	US$61.39k	0.16% € 1.5k
James Daly	Independent Director	7.8yrs	US$51.99k	0.12% € 1.1k
Jon Stonehouse	Interim Independent Chairman	9.2yrs	US$81.89k	0.19% € 1.8k
Reid Huber	Independent Director	9.3yrs	US$64.88k	0.17% € 1.6k
Daniel Powell	Member of Scientific & Clinical Advisory Board	4.9yrs	Nessun dato	Nessun dato
Marco Davila	Member of Scientific & Clinical Advisory Board	4.9yrs	Nessun dato	Nessun dato
Charles Sentman	Member of Scientific & Clinical Advisory Board	4.9yrs	Nessun dato	Nessun dato
Judith Klimovsky	Independent Director	5.2yrs	US$51.99k	0.12% € 1.2k
Gianpietro Dotti	Member of Scientific & Clinical Advisory Board	4.9yrs	Nessun dato	Nessun dato
Malcom Brenner	Member of Scientific & Clinical Advisory Board	4.9yrs	Nessun dato	Nessun dato
Christopher Klebanoff	Member of Scientific & Clinical Advisory Board	no data	Nessun dato	Nessun dato

5.0yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BPXA sono considerati esperti (durata media dell'incarico 5 anni).

Bellicum Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Bellicum Pharmaceuticals, Inc. Announces Board Changes

Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021

Recent updates

Bellicum Pharmaceuticals Files Form 15

The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM).

Nasdaq to Delist the Common Stock of Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from NASDAQ Composite Index

Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1)

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer At ASCO GU Cancers Symposium

Bellicum Pharmaceuticals, Inc. Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

Insufficient new directors

Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Announces Board Changes

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Provides an Operational Update

Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)

Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020

Bellicum Pharmaceuticals, Inc. Announces First Report Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

New 90-day high: €4.46

Bellicum Pharmaceuticals, Inc. Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic Index

Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021

Bellicum Pharmaceuticals, Inc. Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

Bellicum Pharmaceuticals, Inc. Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc. to Reduce Staff by 2020

Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019

New 90-day low - €5.55

Earnings released

The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM).

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value Index

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media